A pharmacokinetic trial with BHV-5000.

Trial Profile

A pharmacokinetic trial with BHV-5000.

Planning
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs BHV 5000 (Primary)
  • Indications Neurological disorders; Rett syndrome
  • Focus Pharmacokinetics
  • Most Recent Events

    • 14 Nov 2017 Accordign to a Biohaven Pharmaceuticals media release, the company is on track to submit an IND by the end of 2017.
    • 23 Jun 2017 New trial record
    • 16 Jun 2017 Accordign to a Biohaven Pharmaceuticals media release, this phase 1 pharmacokinetic trial of BHV-5000 is expected to commence in in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top